Wellstar/TMI Joins Fight Against Bedsores Epidemic

HOLLAND, OH, Jan 12 (MARKET WIRE) --
Wellstar International, Inc. (OTCBB: WLSI), a provider of specialized
diagnostic software and equipment, announced today that its wholly owned
subsidiary, Trillennium Medical Imaging ("TMI"), has now joined the fight
to quell a growing epidemic among patients in the U.S. that are
bed-ridden. Pressure ulcers or decubitus ulcers, commonly known as
bedsores, affect hundreds of thousands of patients admitted to healthcare
facilities and/or long-term care facilities in the U.S. every year.

The Company's revolutionary thermal imaging system allows nursing staff to
objectively identify patterns of injury associated with the development of
pressure ulcers, which can lead to an intervention and even prevention of
bedsores. According to a recent government report, the number of hospital
patients with bedsores has risen dramatically over a 14-year period,
leading to longer, more expensive hospital stays. By identifying the
tissue changes associated with the development of these wounds prior to
skin breakdown, the patient can avoid bedsore occurrences altogether,
therefore receiving better care from the nursing staff at these
facilities.

Wellstar/TMI CEO John Antonio stated, "We are ready to take this serious
epidemic head on. Our team has been aggressively reaching out to educate
the caregivers at these facilities regarding our thermal imaging system
technology. This is a problem that can be eventually eliminated."

For more information on pressure ulcers, please visit: www.npuap.org and
www.bedsores.org

Based on the existing market for TMI's diagnostic system, Wellstar is
anticipating revenues in the current year to exceed $16 million.

ABOUT WELLSTAR INTERNATIONAL, INC.

Wellstar International, Inc., through its wholly owned operating
subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to become a
leading diagnostic company in the health care industry. TMI has developed
and is marketing fully calibrated and functional, thermal imaging systems
that utilize state-of-the-art infrared technologies and proprietary
software to accurately and cost-effectively measure physiological changes
in the human body. More information on the Company and its unique
diagnostic software and product line is available on Wellstar's corporate
Website by visiting: www.wellstar.us

FORWARD-LOOKING STATEMENTS

This press release contains statements, which may constitute
'forward-looking statements' within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Prospective investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward-looking statements. Important factors currently known to
management that could cause actual results to differ materially from
those in forward-statements include fluctuation of operating results, the
ability to compete successfully and the ability to complete
before-mentioned transactions. Specific forward-looking statements
contained in this press release include, but are not limited to, the
Company's assertion that "based on the existing market for TMI's
diagnostic system, Wellstar is anticipating revenues in the current year
to exceed $16 million." The company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions, the
occurrence of unanticipated events or changes to future operating results.

Contact:

Equiti-trend Advisors LLC
(800) 953-3350 Toll-Free, U.S. & Canada
(858) 436-3350 Local or International

Copyright 2009, Market Wire, All rights reserved.

-0-